D-0649-2017 Class III Terminated
FDA drug recall D-0649-2017 was initiated by Dr. Reddy's Laboratories, Inc. on Mar 6, 2017 and is designated Class III. Reason for recall: Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine. The recall status is terminated (terminated Dec 21, 2017). Affected quantity: 1,728 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 12, 2017
- Initiation Date
- Mar 6, 2017
- Termination Date
- Dec 21, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,728 bottles
Product description
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60
Reason for recall
Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Distribution pattern
U.S. nationwide
Code information
Lot #C607323, Exp 10/18
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0649-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026